ABSTRACT
Comparative evaluation of bepotastine besilate versus olopatadine and ketorolac combination onupper tarsal conjunctival brush cytology in patients of vernal keratoconjunctivitis. This studywas a prospective, open label, randomized, comparative clinical study. 100 patients of vernalkeratoconjunctivitis between 6 to 20 years of age of either sex willing to give informed consentwere enrolled in the study. In Group 1, 50 patients received Bepotastine besilate (0.15%) eyedrops twice daily for 8 weeks whereas in Group 2, 50 patients received Olopatadine (0.2%) andKetorolac (0.4%) combination eye drops twice daily for 8 weeks. Upper tarsal conjunctival brushcytology for eosinophil count was done in both the drug groups during the baseline and at 8th weekduring the treatment. It was found that after the 2 months of drug therapy, patients in both thegroups showed reduction in the eosinophil count. However, there was no statistically significantdifference between the two treatment groups at the baseline and at 8th week. There was 32%reduction in group A versus 28% reduction in group B in eosinophil count at the end of 8th weekcompared to baseline. Both bepotastine besilate versus olopatadine and Ketorolac combinationwere found to be effective in reducing the eosinophil count in patients of VKC.
ABSTRACT
Objective: Comparative evaluation of efficacy and safety ofBepotastine besilate versus Olopatadine and Ketorolaccombination in patients with vernal keratoconjunctivitis.Materials and Methods: This was a prospective, open label,randomized, comparative clinical study. Hundred patients ofvernal keratoconjunctivitis between 6 to 20 years of age ofeither sex willing to give informed consent were enrolled in thestudy. In Group 1, 50 patients received Bepotastine besilate(0.15%) eye drops twice daily for 8 weeks whereas in Group 2,50 patients received Olopatadine (0.2%) and Ketorolac (0.4%)combination eye drops twice daily for 8 weeks. Symptoms andsigns scoring of VKC were recorded on baseline and at thetime of follow up at 4 and 8 weeks. Safety assessments werealso done in both the drug groups during the study period forany serious adverse effects.Results: After the 2 months of drug therapy, patients in boththe groups showed improvement in the symptoms and signsscoring of VKC. However, there was no statistically significantdifference between the two treatment groups at 4th and 8thweek. Both the drugs were well tolerated without any seriousadverse effect.Conclusion: Both bepotastine besilate versus olopatadine andKetorolac combination ophthalmic solutions were found to beeffective in alleviating the clinical symptoms and signs of VKC.
ABSTRACT
Ocular itching and redness adversely affect the quality-of-life of vernal keratoconjunctivitis (VKC) patients. The objective of thisstudy was to evaluate changes in VKC patient's quality-of-life (QOL). The present study was prospective, open label,randomized, comparative clinical study. Hundred patients of vernal keratoconjunctivitis between 6 to 20 years of age of eithersex willing to give informed consent were enrolled in the study. In Group A, 50 patients received Bepotastine besilate (0.15%)eye drops twice daily for 8 weeks whereas in Group B, 50 patients received Olopatadine (0.2%) and Ketorolac (0.4%)combination eye drops twice daily for 8 weeks. The Quality of Life Questionnaire (QUICK) is a reliable and validated which wasassessed at baseline and at the time of follow up at 8 weeks. QUICK Questionnaire scores range from 30 to 90 with higher valuesrepresenting greater impairment. A decrease in QUICK Questionnaire score is clinically meaningful to the patients.The results showed that after the 2 months of drug therapy, patients in both the groups showed decrease in the quality of lifescoring of VKC. However, there was no statistically significant difference between the two treatment groups at 8th week. It maybe concluded that both bepotastine besilate versus olopatadine and Ketorolac combination ophthalmic solutions were found to beeffective in alleviating the clinical symptoms and signs of VKC. Hence, improving the quality of life of VKC patients.Keywords: Mast cell stabilizer, Topical NSAIDs, Newer H1-antihistaminics, Vernal keratoconjunctivitis, Quality of life